drugset / Trial / NCT01603641

BOTOX® Open-Label Treatment in Pediatric Lower Limb Spasticity

NCT01603641 ↗

Phase 3 Completed 370 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety of BOTOX® (botulinum toxin Type A) for the treatment of pediatric lower limb spasticity.

Timeline

Start
2012-11-05
Primary completion
2018-08-25
Completion
2018-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 8 iu/kg Intramuscular
Subject Botulinum toxin type A Protein / enzyme biologic 10 iu/kg Intramuscular

Indications